https://mindmedicinelaw.com/briefing/fda-s-2026-psychedelic-drug-trial-guidance-policy-and-research-impact-20260912-41311The Psychedelic Journalen2026-09-12T22:04:14.601776+00:00FDA’s 2026 Psychedelic Drug Trial Guidance: Policy and Research Impactfda psychedelic guidance, clinical trial design, psychedelic research regulation, safety monitoring, trial endpoints, mdma trials, psilocybin regulation, diversity in trials, legal risk, drug development standardshttps://mindmedicinelaw.com/briefing/pharmacology-experience-asymmetry-a-new-framework-for-psychedelic-trials-20260911-41488The Psychedelic Journalen2026-09-13T22:05:16.997318+00:00Pharmacology–Experience Asymmetry: A New Framework for Psychedelic Trialspsychedelic trials, pharmacology–experience asymmetry, experiential variables, clinical trial design, music in psychedelic therapy, regulatory standards, reporting guidelines, mechanistic models, factorial design, FDAhttps://mindmedicinelaw.com/briefing/psilocybin-and-chronic-pain-evidence-mechanisms-and-clinical-gaps-20260911-41487The Psychedelic Journalen2026-09-13T22:05:07.287347+00:00Psilocybin and Chronic Pain: Evidence, Mechanisms, and Clinical Gapspsilocybin, chronic pain, neuropathic pain, central sensitization, clinical trials, neuroplasticity, 5-HT2A receptor, biomarkers, policy implicationshttps://mindmedicinelaw.com/briefing/therapeutic-alliance-and-closeness-in-mdma-therapy-us-pilot-insights-20260911-41469The Psychedelic Journalen2026-09-13T22:04:58.219303+00:00Therapeutic Alliance and Closeness in MDMA Therapy: US Pilot Insightsmdma-assisted therapy, social anxiety disorder, therapeutic alliance, therapist-patient closeness, clinical trial design, psychedelic research, session dynamics, regulatory standards, therapist traininghttps://mindmedicinelaw.com/briefing/dbs-sensing-reveals-ketamine-linked-scc-activity-in-depression-20260911-41500The Psychedelic Journalen2026-09-13T22:04:38.150196+00:00DBS Sensing Reveals Ketamine-Linked SCC Activity in Depressiondeep brain stimulation, ketamine, subcallosal cingulate, treatment-resistant depression, adaptive neuromodulation, chronic brain sensing, frequency bands, personalized psychiatry, clinical trial designhttps://mindmedicinelaw.com/briefing/fda-s-new-psychedelic-framework-policy-and-clinical-impacts-us-2026-20260911-41405The Psychedelic Journalen2026-09-13T15:03:20.558224+00:00FDA’s New Psychedelic Framework: Policy and Clinical Impacts (US, 2026)fda psychedelic framework, psychedelic clinical trials, us psychedelic regulation, integration protocols, clinical trial design, psychedelic therapy policy, research compliance, clinic certification, drug development standards, patient safetyhttps://mindmedicinelaw.com/briefing/culturally-specific-substance-use-treatment-for-black-americans-implications-for-20260910-41489The Psychedelic Journalen2026-09-13T22:06:00.399282+00:00Culturally Specific Substance Use Treatment for Black Americans: Implications for Psychedelic Careblack americans, substance use treatment, psychedelic therapy, cultural competence, structural barriers, community health, health equity, clinical trial design, provider diversityhttps://mindmedicinelaw.com/briefing/ayahuasca-experience-and-mental-health-insights-from-2026-observational-study-20260910-41451The Psychedelic Journalen2026-09-13T22:05:33.386691+00:00Ayahuasca Experience and Mental Health: Insights from 2026 Observational Studyayahuasca, mental health, observational study, ritual settings, psychedelic policy, clinical research, aberrant salience, spiritual well-being, public health, set and settinghttps://mindmedicinelaw.com/briefing/active-deep-dive-therapy-a-new-model-for-mdma-assisted-psychotherapy-20260910-41470The Psychedelic Journalen2026-09-13T22:05:25.716677+00:00Active Deep Dive Therapy: A New Model for MDMA-Assisted Psychotherapymdma-assisted psychotherapy, active deep dive therapy, psychedelic therapy models, free association, clinical trial design, unconscious processing, patient selection, transdiagnostic approach, therapeutic mechanisms, psychoanalytic integrationhttps://mindmedicinelaw.com/briefing/fda-data-flags-ibogaine-mitragynine-cardiac-risks-in-us-review-20260910-41449The Psychedelic Journalen2026-09-13T22:04:49.612281+00:00FDA Data Flags Ibogaine, Mitragynine Cardiac Risks in US Reviewibogaine, mitragynine, kratom, cardiac arrhythmia, QTc prolongation, FDA adverse event reporting, psychedelic safety, clinical trial design, regulatory policy, pharmacovigilancehttps://mindmedicinelaw.com/briefing/subjective-effects-in-psychedelic-trials-policy-and-clinical-implications-20260909-41132The Psychedelic Journalen2026-09-12T15:03:45.282612+00:00Subjective Effects in Psychedelic Trials: Policy and Clinical Implicationspsychedelic therapy, subjective effects, clinical trial design, regulatory policy, non-hallucinogenic analogs, therapeutic mechanisms, FDA guidance, insurance reimbursement, psychedelic experience, neurosciencehttps://mindmedicinelaw.com/briefing/real-world-use-of-ketamine-esketamine-ect-and-rtms-in-tertiary-mood-disorder-cli-20260908-41512The Psychedelic Journalen2026-09-13T22:05:52.111634+00:00Real-World Use of Ketamine, Esketamine, ECT, and rTMS in Tertiary Mood Disorder Clinicsinterventional psychiatry, ketamine, esketamine, electroconvulsive therapy, rTMS, mood disorders, treatment resistance, real-world evidence, tertiary care, service planninghttps://mindmedicinelaw.com/briefing/transformer-model-uncovers-psilocybin-s-cell-type-transcriptional-effects-20260908-41497The Psychedelic Journalen2026-09-13T22:05:42.454769+00:00Transformer Model Uncovers Psilocybin’s Cell-Type Transcriptional Effectspsilocybin, transformer model, single-cell transcriptomics, gene expression, HTR2A, biomarker discovery, clinical trial design, neuroscience, artificial intelligence, psychedelic research